On October 21, 2011, the U.S. Department of Justice announced that the pharmaceutical manufacturer, Pfizer Inc., agreed to pay $14.5 million to resolve alleged violations of the False Claims Act related to Detrol, a drug marketed for a condition called overactive bladder.
New York State Attorney General Eric T. Schneiderman announced last week that the state has reached a settlement with food service provider Whitsons Culinary Group for illegally overcharging school districts and other education providers.
On October 6, 2011, federal authorities announced the settlement of a health care fraud lawsuit against the trustees of Columbia University, New York Presbyterian Hospital, and Dr. Erik Goluboff for $995,000. The settlement resolves allegations that the defendants caused Medicare to be over-billed for urological procedures and billed for urological tests that were medically unnecessary.
Last week, Oracle Corp. and Oracle America, Inc. agreed to pay $199.5 million plus interest for failing to meet their contractual obligations to the General Services Administration (GSA). The settlement resolves a lawsuit filed on behalf of the U.S.
On October 3, 2011, counsel for whistleblower and qui tam Plaintiff Beatrice Maitland announced the settlement of False Claims Act allegations against a subsidiary of Select Medical Corporation for suspect “Medical Director” payments made to various physicians. Specifically, Select Specialty Hospital–Columbus, Inc. agreed to pay $7.
On Friday September 30, 2011, the U.S. Department of Justice announced that home health provider LHC Group, Inc.
Both the SEC and the Department of Justice are investigating whether Motorola bribed European officials in exchange for business. The investigation resulted from Motorola’s own internal investigation of suspicious transactions within Turkey, which was reported to United States authorities. The probe expanded to Motorola’s transactions in Europe involving a lobbyist previously investigated for bribery.
The SEC has filed a civil complaint against Corey Ribotsky and his hedge fund, NIR Group of fraud by concealing losses and using investor funds for personal expenses. The Complaint alleges that Ribotsky misappropriated over $1 million in client funds and using the funds for automobile payments and jewelry.
A federal district court has ruled that in order to bring a claim for retaliation under the Dodd-Frank Act’s securities whistleblower retaliation provisions, the purported whistleblower must submit information to the Securities and Exchange Commission. In Egan v. Tradingscreen, Inc., (No. 10 Civ. 8202, (S.D.N.Y.
A wholly owned subsidiary of Boston Scientific agreed to pay $9.25 million to the U.S. to settle False Claims Act allegations that it overcharged federal health programs for replacement pacemakers and defibrillators.
According to allegations in a qui tam suit filed by whistleblower Robert A.
If you are aware of any person, corporation or entity that you think may be violating the Federal False Claims Act or a State False Claims Act, contact us today.